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doi:10.1016/j.kjms.2011.06.024Abstract Red cell distribution width (RDW) was found to be a prognostic marker in heart
failure patients. The aim of the study was to investigate the relationship between RDW and
echocardiographic parameters in diastolic heart failure (DHF). Seventy-one consecutive DHF
patients (26 men) and 50 controls (21 men) were included in the study. All of the study popula-
tion underwent echocardiographic evaluation, and blood samples were obtained. RDW and
N-terminal pro-B-type natriuretic peptide (NT-proBNP) values were significantly higher,
whereas there was an increasing trend for high-sensitivity C-reactive protein levels in DHF
patients than those in controls (p< 0.001, p< 0.001, and pZ 0.064, respectively). All of the
echocardiographic parameters evaluating diastolic function were more deteriorated in the
DHF group. Patients who had an RDW value greater than the cutoff point also had higher
NT-proBNP levels, an elevated ratio of mitral peak velocity of early diastolic filling to early dia-
stolic mitral annular velocity, and increased estimated pulmonary capillary wedge pressures by
tissue Doppler parameters, but lower creatinine clearance (p< 0.05 for all). According to the
cutoff values calculated using receiver operating characteristic analysis, RDW> 13.6% and
NT-proBNP> 125 pg/mL have high diagnostic accuracy for predicting DHF. RDW values were
increased in the DHF population. Our results suggest that the high RDW levels in patients with
DHF may be related to increased neurohormonal activity, impaired renal functions, and
elevated filling pressure, but not to increased inflammation.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.asa Universitesi, Arastirma Hastanesi Kardiyoloji AD, Eski Rektorluk Binasi, Tokat 60100, Turkey.
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Diastolic heart failure (DHF) is a clinical syndrome charac-
terized by the symptoms and signs of heart failure,
a preserved ejection fraction, and abnormal diastolic
function [1]. Various definitions, such as “heart failure with
preserved systolic function” or “heart failure with normal
or near normal ejection fraction” have also been used [2].
The proportion of patients with DHF in epidemiological
studies ranges from 40% to 71% (mean, 56%), but in hospital-
based cohort studies, it is slightly lower, ranging from 24%
to 55% (mean, 41%) [3]. Older age; hypertension with left
ventricular hypertrophy; pathologies, such as diabetes,
obesity, coronary artery disease (CAD), and new onset atrial
fibrillation are commonly associated with DHF [2,3].
Red cell distribution width (RDW) is a quantitative
measure of anisocytosis, the variability in size of the
circulating erythrocytes, and is routinely reported by
automated laboratory equipment used to perform complete
blood counts [4]. Higher RDW values indicate that a greater
variety of cell sizes is present. In clinical practice, RDW is
generally used to narrow the differential diagnosis of
anemia, especially to differentiate iron deficiency anemia
and thalassemia [5,6]. Recently, there has been growing
attention given to the relationship between RDW and
cardiovascular disorders, such as heart failure and CAD. This
interest was spurred by the report from Felker et al. [7],
which showed that there is a strong, independent associa-
tion between RDW and the risk of adverse outcomes in heart
failure patients, and the study by Tonelli et al. [8], which
predicted a graded independent relationship between RDW
and the risk of death and cardiovascular events in patients
with CAD.
Although the prognostic importance of RDW in various
cardiovascular diseases, including systolic heart failure, is
well known, there are no data about RDW in the DHF
population. The purpose of the present study was to
determine if RDW levels are significantly different in DHF
patients compared with those of controls and to investigate




Seventy-one consecutive patients [mean age, 57 7 years;
26 (37%) men] diagnosed with DHF in our clinic and 50
controls [mean age, 56 7 years; 21 (42%) men] were
included in the study. DHF was diagnosed when symptoms
(dyspnea not associated with any other cause) and signs
(rales or peripheral edema) of heart failure were observed
along with a preserved left ventricular ejection fraction
(LVEF 50%) and evidence of diastolic dysfunction. The
control group was formed from voluntary individuals
admitted to our clinic who did not have heart failure
symptoms and signs and who had a preserved LVEF. Patients
with systolic heart failure; hemodynamically unstable
valvular heart disease; congenital heart disease; atrial
fibrillation; chronic obstructive pulmonary disease; malig-
nancy; known hematological diseases, such as hemolyticanemia, neoplastic metastases in the bone marrow; preg-
nancy; severe arthritis and inflammatory bowel diseases
that can increase plasma RDW levels and other extracel-
lular fluid increasing diseases, such as hypothyroidism and
liver cirrhosis, were excluded from the study. The patient
group was divided into two according to the most appro-
priate cutoff point of RDW calculated for predicting DHF
(RDW 13.6%, RDW> 13.6%).
The present study was a single-center study. All exami-
nations were performed by the cardiology clinic of our
hospital. All participants gave their informed consent
before inclusion in the study. The study protocol was
approved by the local committee at our institution.
Echocardiographic measurements
All of the study population underwent echocardiographic
evaluation individually on the day of their admission (2.5-
mHz transducer; Philips EnVisor C, Bothell, WA, USA).
Standardized projections and measurements were per-
formed for the evaluation of cardiac anatomy, ventricular
function, and valve competence. LVEF was measured by
Simpson’s method [9]. Left ventricular mass was calculated
by the formula described by Devereux et al., and left
ventricular mass index was obtained by dividing the left
ventricular mass by the body surface area [10]. The
following conventional mitral inflow pulse wave Doppler
parameters were measured: peak velocity of early diastolic
filling and late filling, and deceleration time of the E-wave
velocity. These parameters were obtained from the apical
four-chamber view with a 1-mm to 3-mm sample volume
placed between the mitral leaflet tips during diastole.
Pulmonary venous flow parameters were also measured:
peak systolic velocity (Ps), peak antegrade diastolic
velocity (Pd), and the Ps/Pd ratio. These parameters were
obtained from the apical four-chamber view with a 2-mm to
3-mm sample volume placed 1 cm into the pulmonary vein.
Tissue Doppler parameters were measured: peak systolic
mitral annular velocity, early diastolic mitral annular
velocity (Em), and late diastolic mitral annular velocity
(Am). These parameters were obtained from the apical
four-chamber view with a 2-mm to 5-mm sample volume
placed 1 cm within the septal and lateral insertions of the
mitral leaflets. The mean of three or more measurements
was used for analysis of the Doppler data. The ratio of
mitral peak velocity of early diastolic filling to early dia-
stolic mitral annular velocity (E/Em) was calculated for the
lateral and septal annulus, and the mean of the lateral
and septal E/Em were also determined. As previously
described, the formula (1.24 (E/Em)þ 1.9) was used to
estimate pulmonary capillary wedge pressure (PCWP) [11].
Diastolic dysfunction is defined as Em< Am if Em is less
than 10 cm/s in lateral mitral annulus or less than 8 cm/s in
septal mitral annulus [12].
Biochemical measurements
Blood samples were obtained during admission for routine
chemistry, including N-terminal pro-B-type natriuretic
peptide (NT-proBNP) and high-sensitivity C-reactive protein
(hs-CRP) after an overnight fast. RDW values were measured
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in our hospital laboratory. NT-proBNP analyses were made
by the electrochemiluminescence immunoassay method
(Cobas 6000 analyzer; ROCHE Diagnostics GmbH, Mannheim,
Germany), and hs-CRP analyses were made using the
immunonephelometry method (Dade Behring, Inc., BN
Prospect, Marburg, Germany) in our hospital laboratory. The
Cockcroft-Gault formula was used to calculate creatinine
clearance [13].
Statistical analysis
According to Kolmogorov-Smirnov normality test, two
independent-sample t tests were used to compare the
normally distributed independent variables between two
groups, and Mann-Whitney U test was used to compare the
non-normally distributed independent variables between
two groups. Normally distributed continuous data were
expressed as mean standard deviation; non-normally
distributed continuous variables were presented as
median and interquartile range (Quartiles le3). Chi-square
test was used for comparing the categorical data. Cate-
gorical data were expressed as count and percentages. A
receiver operating characteristic (ROC) curve was con-
structed for RDW and NT-proBNP to test the effectiveness
of various cutoff points in predicting DHF. The area under
the ROC curve was calculated; the sensitivity and speci-






Coronary artery disease 10
Smoking 10
Renin-angiotensin system blockers 15
b-Blockers 12
Calcium channel blockers 9 (1
Statins 8 (1
Aspirin 19
Body mass index (kg/m2) 30.
Systolic blood pressure (mmHg) 130
Diastolic blood pressure (mmHg) 81.
Glucose (mg/dL) 100
Thyroid stimulating hormone (mIU/mL) 1.5
Creatinine (mg/dL) 0.7
Creatinine clearance (mL/min/1.73 m2) 115
Cholesterol (mg/dL) 198
Triglyceride (mg/dL) 164
Low-density-lipoprotein cholesterol (mg/dL) 125
High-density-lipoprotein cholesterol (mg/dL) 44.
Hemoglobin (g/dL) 13.
Red cell distribution width (%) 12.
N-terminal pro-B-type natriuretic peptide (pg/mL) 57
High-sensitivity C-reactive protein (mg/L) 3.1
Data are shown as n (%), mean standard deviation, or median (inte
a Calculated by log-transformed data.cutoff point were calculated for predicting DHF. Spear-
man’s correlation test was used for correlation between
variables. A multivariate logistic regression model was
implemented to determine RDW, NT-proBNP, and other
covariates associated with DHF. A p value less than 0.05 was
considered statistically significant. Statistical analysis was
performed by using commercial software (IBM SPSS Statis-
tics 19, SPSS Inc., an IBM Co., Somers, NY, USA).
Results
Baseline characteristics and the differences
between the patient and the control groups
There were no significant differences between the patient
and the control groups with regard to age, sex, hyperten-
sion, diabetes, CAD, smoking, medications, body mass
index, fasting blood glucose, thyroid status, lipid profile,
creatinine clearance, serum creatinine, and hemoglobin
levels (Table 1). The patient group had higher blood pres-
sure, more hypertrophy in the left ventricle, and a bigger
left atrial size (Tables 1 and 2). RDW and NT-proBNP
were significantly higher in the patient group [RDW:
12.99% 1.34% vs. 14.33% 1.53%, p< 0.001; NT-proBNP:
57 pg/L (26e94 pg/L) vs. 97 pg/L (57e264 pg/L), p< 0.001]
(Table 1). hs-CRP was also higher in the patient group, but
this difference did not reach significant levels [3.19 mg/dLient and control groups.
trol (nZ 50) Patient (nZ 71) p
16 6.98 57.09 7.43 0.491
(42.0) 26 (36.6) 0.550
(48.0) 43 (60.6) 0.171
(28.0) 20 (28.2) 0.984
(20.0) 21 (29.6) 0.235
(20.0) 13 (18.3) 0.816
(30.0) 33 (46.5) 0.068
(24.0) 23 (32.4) 0.316
8.0) 10 (14.1) 0.560
6.0) 14 (19.7) 0.602
(38.0) 26 (36.6) 0.877
30 4.10 31.33 4.14 0.179
.00 20.73 139.79 20.06 0.011
00 11.65 86.41 11.75 0.014
(92e115) 105 (92e122) 0.218a
4 0.95 1.44 0.95 0.597
6 0.18 0.78 0.23 0.469
.79 28.17 113.01 33.76 0.638
.31 39.94 196.24 42.20 0.788
.37 86.34 152.61 62.35 0.388
.43 32.79 125.37 36.71 0.992
00 11.17 46.85 11.93 0.190
75 1.64 13.38 1.53 0.208
99 1.34 14.33 1.53 <0.001
(26e94) 97 (57e264) <0.001a
9 (3.19e5.60) 3.27 (3.22e4.46) 0.064
rquartile range).
Table 2 Echocardiographic parameters of patient and control groups.
Variables Control (nZ 50) Patient (nZ 71) p
Left ventricular ejection fraction (%) 68 (63e73) 72 (63e75) 0.339
Left ventricular end-diastolic dimension (mm) 47.06 5.84 46.27 5.42 0.445
Left ventricular end-systolic dimension (mm) 29.66 4.68 30.21 4.52 0.516
Interventricular septal dimension (mm) 10.70 1.94 11.69 1.95 0.007
Posterior wall dimension (mm) 9 (9e11) 11 (10e12) <0.001
Left atrium diameter (mm) 34.18 4.14 38.04 5.48 <0.001
Left ventricular mass index (g/m2) 91.02 20.38 103.11 24.33 0.005
Ratio of peak systolic velocity and peak antegrade
diastolic velocity of pulmonary venous flow
1.3 (1.1e1.4) 0.9 (0.8e1.3) 0.001
E (cm/s) 65.14 17.45 77.87 20.30 <0.001
A (cm/s) 78.18 22.41 83.81 22.98 0.182
E/A 0.8 (0.7e1.0) 0.9 (0.7e1.0) 0.157
Deceleration time of the E-wave velocity (ms) 211.38 46.27 215.99 43.48 0.577
Lateral
Sm (cm/s) 9.37 2.03 8.91 2.11 0.232
Em (cm/s) 10.87 1.81 8.70 1.91 <0.001
Am (cm/s) 11.64 2.38 11.88 2.88 0.619
Em/Am 0.87 (0.75e1.20) 0.72 (0.64e0.85) <0.001
E/Em 6.06 1.56 9.43 3.33 <0.001
PCWP (mmHg) 9.00 (7.98e10.82) 12.63 (11.36e15.44) <0.001
Septal
Sm (cm/s) 8.11 1.45 7.65 1.61 0.112
Em (cm/s) 8.72 1.25 6.70 1.56 <0.001
Am (cm/s) 10.54 1.76 10.31 2.26 0.548
Em/Am 0.85 0.18 0.66 0.14 <0.001
E/Em 7.53 2.02 12.11 3.89 <0.001
PCWP (mmHg) 11.24 2.50 16.92 4.82 <0.001
E/Em mean 6.46 (5.33e7.96) 9.85 (8.74e11.45) <0.001
PCWP mean (mmHg) 9.91 (8.51e11.77) 14.12 (12.74e16.09) <0.001
Data are shown as mean standard deviation or median (interquartile range).
AZ peak velocity of late filling; AmZ late diastolic mitral annular velocity; EZ peak velocity of early diastolic filling; E/EmZ early
mitral inflow velocity to early diastolic mitral annular velocity ratio; EmZ early diastolic mitral annular velocity; PCWPZ pulmonary
capillary wedge pressure; SmZ peak systolic mitral annular velocity.
168 A. Celik et al.(3.19e5.60 mg/dL) vs. 3.27 mg/dL (3.22e4.46 mg/dL),
pZ 0.064] (Table 1). The mitral E; lateral, septal, and
mean E/Em; and the PCWP estimated from each of the
E/Em measurements were all significantly higher, whereas
Ps/Pd, lateral and septal Em, and lateral and septal Em/Am
were significantly lower in the patient group (Table 2).
Relationship between RDW and study parameters
The most appropriate cutoff point calculated for predicting
DHF was 13.6%. The patients who had an RDW value equal
or less than 13.6% were included in the “lower RDW” group.
The remaining formed the “higher RDW” group.
There were no significant differences between the lower
and higher RDW groups with regard to age, sex, diabetes,
CAD, smoking, medications except statin and aspirin, body
mass index, fasting blood glucose, thyroid status, and
hemoglobin levels (Table 3). Hypertension was significantly
higher in the “higher RDW” group, but systolic and diastolic
blood pressures were similar (Table 3). Cholesterol levels
were lower, and the number of patients on statin therapy
was higher in the “higher RDW” group (Table 3). Serum
creatinine was significantly higher, and creatinineclearance was significantly lower in the “higher RDW” group
(Table 3). There were no significant differences in the LVEF,
left ventricular mass index, Ps/Pd ratio, E/A, and lateral
and septal Em/Am of the “lower RDW” and “higher RDW”
groups (Table 4). The mean E/Em and estimated mean
PCWP were significantly higher in the “higher RDW” group
(Table 4). NT-proBNP was significantly higher in the “higher
RDW” group, but this difference was not seen in the hs-CRP
levels (Table 4).
RDW positively correlated with NT-proBNP (p< 0.001,
rZ 0.373); mean E/Em (p< 0.001, rZ 0.385); estimated
mean PCWP (p< 0.001, rZ 0.385); and hs-CRP (pZ 0.007,
rZ 0.246) in the study population. When we performed the
same analysis for DHF patients, results were significant for
NT-proBNP (pZ 0.004, rZ 0.316); mean E/Em (pZ 0.035,
rZ 0.227); and estimated mean PCWP (pZ 0.035,
rZ 0.227), but not for hs-CRP (pZ 0.093, rZ 0.202).
According to the cutoff values calculated using ROC
analysis, RDW> 13.6% and NT-proBNP> 125 pg/mL have
high diagnostic accuracy for predicting DHF (area under the
ROC curveZ 0.736, p< 0.001 and area under the ROC
curveZ 0.725, p< 0.001, respectively). There was also no
significant difference for diagnostic accuracy between the
Table 3 Baseline characteristics and laboratory findings of lower and higher RDW groups.
Variables Lower RDW (13.6%) (nZ 25) Higher RDW (>13.6%) (nZ 46) p
Age (y) 57 7 57 8 0.924
Gender (male) 8 (32) 18 (39) 0.551
Hypertension 10 (40) 33 (71) 0.009
Diabetes 8 (24) 14 (30) 0.565
Coronary artery disease 7 (28) 14 (30) 0.830
Smoking 3 (12) 10 (22) 0.311
Renin-angiotensin system blockers 8 (32) 25 (54) 0.071
b-Blockers 6 (24) 17 (37) 0.265
Calcium channel blockers 3 (12) 7 (15) 0.710
Statins 0 (0) 14 (30) 0.002
Acetyl salicylic acid 4 (16) 22 (48) 0.008
Body mass index (kg/m2) 32 4 31 4 0.707
Systolic blood pressure (mmHg) 137 20 141 20 0.463
Diastolic blood pressure (mmHg) 87 11 86 12 0.838
Glucose (mg/dL) 111 33 118 40 0.494
Thyroid stimulating hormone (mIU/mL) 1.19 0.78 1.58 1.01 0.102
Creatinine (mg/dL) 0.58 0.78 0.90 0.21 <0.001
Creatinine clearance (mL/min/1.73 m2) 140 26 97 27 <0.001
Cholesterol (mg/dL) 214 50 187 34 0.008
Triglyceride (mg/dL) 152 55 153 67 0.927
Low-density-lipoprotein cholesterol (mg/dL) 139 43 118 30 0.016
High-density-lipoprotein cholesterol (mg/dL) 48 12 46 12 0.434
Hemoglobin (g/dL) 13.9 1.2 13.1 1.6 0.057
N-terminal pro-B-type natriuretic peptide (pg/mL) 70 (57e106) 191 (57e560) 0.006a
High-sensitivity C-reactive protein (mg/L) 4.33 2.22 5.05 3.74 0.227
Data are shown as n (%), mean standard deviation, or median (interquartile range).
RDWZ red cell distribution width.
a Calculated by log-transformed data.
Red cell distribution width in heart failure 169two methods (pZ 0.898) (Table 5 and Fig. 1). According to
multivariate logistic regression model (adjusted for systolic
and diastolic blood pressure and left atrium diameter),
when RDW value increases by 1 unit, risk of DHF increases
1.84 times, and when NT-proBNP value increases by 1 unit,
risk of DHF increases 1.01 times (Table 6).Table 4 Echocardiographic parameters of lower and higher RD
Variables Lower RD
Left ventricular ejection fraction (%) 70
Left ventricular mass index (g/m2) 104
Ratio of peak systolic velocity and peak antegrade
diastolic velocity of pulmonary venous flow
0.9
Ratio of peak velocity of early diastolic filling to peak
velocity of late filling
0.8
Ratio of early mitral inflow velocity to early diastolic
mitral annular velocity, lateral
0.7
Ratio of early diastolic mitral annular velocity to late
diastolic mitral annular velocity, septal
0.6
Ratio of early mitral inflow velocity to early diastolic
mitral annular velocity, mean
9.4
Pulmonary capillary wedge pressure, mean (mmHg) 13
Data are shown as mean standard deviation or median (interquartil
RDWZ red cell distribution width.Discussion
This study has shown that the RDW is elevated in the DHF
population, and that higher RDW levels are associated with
higher NT-proBNP levels and elevated left ventricular filling
pressures (LVFPs) in DHF patients.W groups.
W (13.6%) (nZ 25) Higher RDW (>13.6%) (nZ 46) p
 8 68 7 0.279
 26 103 24 0.865
(0.8e1.3) 0.9 (0.8e1.2) 0.887
1 (0.69e0.97) 0.87 (0.74e1.06) 0.133
2 0.14 0.79 0.25 0.198
3 0.11 0.68 0.15 0.229
(8.7e10.1) 10.6 (8.5e14.0) 0.047
(13e14) 15 (12e19) 0.047
e range).
Table 5 Comparison of diagnostic accuracy for diastolic heart failure between RDW and NT-proBNP.
Variables Cutoff value AUC 95% CI of AUC Sensitivity Specificity pa pb
RDW (%) >13.6 0.736 0.648e0.812 0.648 0.700 <0.001 0.898
NT-proBNP (pg/mL) >125.0 0.725 0.635e0.803 0.449 0.960 <0.001 d
AUCZ area under the receiver operating characteristic curve; CIZ confidence interval; NT-proBNPZ N-terminal pro-B-type natriuretic
peptide; RDWZ red cell distribution width.
a Significant level of AUC.
b Comparison between RDW and NT-proBNP.
170 A. Celik et al.RDW is a quantitative measure of anisocytosis, which is
the variability in size of the circulating erythrocytes, and is
routinely measured by automated laboratory equipment
used to perform complete blood counts [4]. There are
several hematological reasons for elevated RDW, such as
iron deficiency anemia, hemolytic disorders, vitamin B12
and folate deficiency, and thrombotic thrombocytopenic
purpura [14e17]. It has also been shown that RDW levels
are elevated in stroke, colon cancer, inflammatory bowel
disease, pregnancy, and pulmonary hypertension [18e22].
Moreover, RDW has been found to be the predictor of all-
cause deaths in two community-based cohorts [23,24].
Recently, RDW has been shown to be a novel marker for
predicting outcomes in the heart failure population
[7,25,26]. It has been concluded that RDW independently
predicts 1-year mortality after an acute heart failure
episode, and high RDW values also predict poor long-term
outcome regardless of anemia status in acute heart
failure patients [27,28]. High RDW values are also associ-
ated with increased risk of death and cardiovascular events
in people with prior myocardial infarction without symp-
tomatic heart failure, all-cause mortality in an unselected
population referred for coronary angiography, mortality
after acute myocardial infarction, adverse outcomes in
patients with acute coronary syndrome, and long-term
mortality in patients undergoing percutaneus coronary
intervention [8,29e32].
There are several potential mechanisms to explain
elevated RDW values in heart failure. Previous studies haveFigure 1. Receiver operating characteristic curve showing
the relationship between sensitivity and false positivity at
various cutoff points for red cell distribution width (RDW) and
N-terminal pro-B-type natriuretic peptide (NT-proBNP) to
predict diastolic heart failure.addressed inflammation, ineffective erythropoiesis,
malnutrition, impaired renal function, and neurohormonal
activation in heart failure patients [26].
Because our study is the first to evaluate the relationship
between RDW and DHF, there is no information about the
possible mechanism for RDW elevation in this population.
According to Kitzman et al. [33], neurohormonal abnor-
malities similar to those observed in systolic heart failure
occur in DHF. In the present study, RDW was shown to be
correlated both with NT-proBNP and hs-CRP for our study
population, but the correlation between hs-CRP and RDW
remained insignificant for the patient group. Moreover,
there were also no significant differences in hs-CRP values
between the patient and the control groups. This suggests
that neurohormonal activation may be more effective for
RDW elevation in this population than inflammation. Van
Kimmenade et al. [27] also demonstrated that the elevation
of RDW in acute heart failure patients did not appear to be
associated with nutritional status, transfusion history, or
inflammation. On the other hand, Allen et al. [34] very
recently showed that elevated RDW may indicate inflam-
matory stress and impaired iron mobilization in heart
failure population.
Previous studies show that elevated NT-proBNP values
are diagnostic of DHF and are associated with elevated
LVFP [35,36]. It has been found that there is a strong
correlation between NT-proBNP and E/Em, and a threshold
of 269.1 pg/mL of NT-proBNP predicted an E/Em> 15 with
90% sensitivity and 73% specificity in DHF [37]. The positive
correlation between elevated RDW and NT-proBNP, E/Em,
and PCWP in our study implies that increases in LVFP could
be the underlying mechanism for RDW elevation in patients
with DHF. Oh et al. [38] found that there is an association
between RDW elevation and E/Em in acute heart failure
patients, and that the optimal cutoff value of RDW for
predicting E/Em> 15 is 13.45%. We observed significant
differences related to NT-proBNP, mean E/Em, and esti-
mated mean PCWP values in the two groups divided
according to the cutoff value of RDW for predicting DHF
(13.6%). Hampole et al. [22] found that in patients with
pulmonary hypertension and right heart failure, elevated
RDW is associated with mortality, but there is no correla-
tion with hemodynamic parameters. Based on this finding,
the elevation in RDW is not only explained by hemodynamic
abnormalities.
Renal functions were significantly more impaired in our
“higher RDW” group. Fo¨rhe´cz et al. [26] previously
addressed impaired renal function as one of the possible
mechanism for RDW elevation in patients with heart failure.
A similar mechanism may also be responsible for the higher
RDW values in DHF patients.
Table 6 Comparison of diastolic heart failure and RDW and NT-proBNP in multivariate logistic regression model.
Variables b OR 95% CI for OR p
RDW 0.609 1.838 1.284e2.630 0.001
Systolic blood pressure 0.022 1.022 1.001e1.044 0.042
Left atrium diameter (mm) 0.156 1.169 1.057e1.293 0.002
NT-proBNP 0.011 1.011 1.003e1.019 0.006
Systolic blood pressure 0.046 1.047 1.008e1.088 0.017
Left atrium diameter (mm) 0.141 1.151 1.037e1.278 0.008
CIZ confidence interval; NT-proBNPZ N-terminal pro-B-type natriuretic peptide; ORZ odds ratio; RDWZ red cell distribution width.
Red cell distribution width in heart failure 171The lower cholesterol levels in our “higher RDW” group
can be explained by the greater proportion of patients on
statin therapy. Our DHF group had higher systolic blood
pressure, more hypertrophy in the left ventricle, and bigger
left atrial size. This is an expected result because
hypertension-hypertrophy is one of the etiologies of DHF.
There are potential limitations of this study. First, the
sample size was relatively small. Second, despite the
evidences that E/Em is a good noninvasive predictor of
LVFP, we did not measure left ventricular pressures
directly. Third, we did not measure vitamin B12 and folate
levels, which are one of the potential causes of increased
levels of RDW. However, our study population is not
anemic, and the possible effect of these vitamin defi-
ciencies may be unimportant. Fourth, we also did not
evaluate the nutritional status, which has been previously
suggested as a potential cause of RDW increase. Finally, it
may not be true to suggest that neurohormonal activation is
the major underlying mechanism for RDW elevation in DHF
population according to the correlation found between
RDW and NT-proBNP alone. Measurements of renin, angio-
tensin II, and epinephrine can help make more accurate
inferences.
In conclusion, RDW values were increased in the DHF
population. Our results suggest that high RDW levels in
patients with DHF may be related to increased neurohor-
monal activity, impaired renal functions, and elevated
filling pressure, but not to increased inflammation. RDW
can be used as an additive marker for predicting elevated
LVFP in patients with DHF at no additional cost. However,
further studies are required to solve the underlying mech-
anism for the RDW increase in this population.References
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